Evidence map›Paper›PMID 40138148›Full record

Observational studyJournal of endocrinological investigation2025

Cardiometabolic complications after Cushing's disease remission.

Irene Tizianel, Laura Lizzul, Alessandro Mondin, Giacomo Voltan, Pierluigi Mazzeo, Carla Scaroni, Mattia Barbot, Filippo Ceccato

Abstract readObservational Study
In one paragraph

Observational study in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Distinct plasma protein profiles after long-term remission of Cushing's disease.The Journal of clinical endocrinology and metabolism · 2026
    Article
  2. Article
  3. Review
  4. European survey on metabolic and cardiovascular risk in Cushing syndrome.Journal of endocrinological investigation · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irene TizianelDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Laura LizzulDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Alessandro MondinDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Giacomo VoltanDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Pierluigi MazzeoDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Carla ScaroniDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Mattia BarbotDepartment of Medicine-DIMED, University of Padova, Padova, Italy.
Filippo CeccatoDepartment of Medicine-DIMED, University of Padova, Padova, Italy. filippo.ceccato@unipd.it.ORCID http://orcid.org/0000-0003-1456-8716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimCushing's disease (CD) is associated with phenotypic traits and comorbidities that may persist after the normalization of cortisol levels. Medical therapy is usually given in recurrent or persistent CD after transsphenoidal surgery. We aimed to investigate the impact of long-term normalization of daily cortisol secretion on clinical picture and cardiometabolic comorbidities, comparing surgical remission to medical treatment.

methodsMonocentric retrospective study, two- and five-years observation. Sixty CD patients, with sustained normal 24-h urinary free cortisol (UFC) levels, divided group 1 (surgical remission, n = 36) and group 2 (medical remission, n = 24).

resultsPatients were different after achieving eucortisolism with surgery or medical treatment. Phenotypic traits: round face, dorsocervical fat pad, and bruisability persisted more prominently in the group 2, however abdominal obesity and muscle weakness persisted in both groups, especially in those patients with increased late-night salivary cortisol (LNSC). HYPERTENSION: greater improvement was observed in group 1 (-31% vs. -5%, p = 0.04). Diabetes: less prevalent in group 1 after 2 years (2/36 vs. 9/24, p = 0.002), with a corresponding reduction in glucose-lowering treatments and persistence of impaired LNSC in diabetic patients (p < 0.001). Dyslipidemia: remained widespread in both groups, with minimal improvement over time (-22% in surgical and - 6% in medical cohort).

conclusionsSurgical remission leads to faster and sustained improvements in clinical phenotype. However, obesity, arterial hypertension, and dyslipidemia do not completely revert in five years, especially during medical treatment. Most comorbidities persist despite UFC normalization, due to impaired LNSC: the recovery of cortisol rhythms confirms the remission of hypercortisolism.

Indexed as

Cardiovascular DiseasesMetabolic DiseasesPituitary ACTH HypersecretionAdultFemaleFollow-Up StudiesHumansHydrocortisoneMaleMiddle AgedPrognosisRemission InductionRetrospective StudiesHydrocortisoneCushing’s diseaseCushing’s disease medical therapyCushing’s disease medical treatmentCushing’s disease neurosurgeryHypercortisolism remission

Identifiers

PMID40138148
PMCPMC12313713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.